Skip to content
OpenCapital
Get started

Zymeworks ZYME Available-for-Sale Debt Securities - Amortized Cost (Due Within One Year)

Available-for-Sale Debt Securities - Amortized Cost (Due Within One Year) at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
——

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.79B+125%

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's available-for-sale debt securities - amortized cost (due within one year).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's available-for-sale debt securities - amortized cost (due within one year)?
Zymeworks (ZYME) reported available-for-sale debt securities - amortized cost (due within one year) of $120.41M in Q1 2026.
How has Zymeworks's available-for-sale debt securities - amortized cost (due within one year) changed year-over-year?
Zymeworks's available-for-sale debt securities - amortized cost (due within one year) decreased by 36.3% year-over-year, from $188.94M to $120.41M.
What is the long-term trend for Zymeworks's available-for-sale debt securities - amortized cost (due within one year)?
Over 2 years (2023 to 2025), Zymeworks's available-for-sale debt securities - amortized cost (due within one year) has grown at a -6.9% compound annual growth rate (CAGR), from $216.38M to $187.46M.